About StemCells, Biomedicine, Diet Impact, Mental Health, Meditation,Viruses & Regenerative Medicine

[farrell90]

Additional background about Molnupiravir:

- its mechanism of action is similar to Remdesivir and Favipiravir as a nucleoside analogue

- it has only completed a phase 1 study in healthy volunteers

- its large phase 2 trials are still recruiting patients

-it is was purchased from Emory University by a hedge fund

- the hedge fund owner,Rick Holman, is listed as an author of the Phase 1 study publication

-The hedge fund company's Ridgeback Biotherapeutics has been accused of improper influence in seeking Barda funds

-Former Barda chief Dr Rick Bright stated, "similar experimental drugs in this class had been shown to cause reproductive toxicity in animals, and offspring from treated animals had been born without teeth and without parts of their skulls."

-Bright also stated,"illegally retaliated against him for objecting to what he saw as improper and unscientific efforts to steer taxpayer dollars to certain firms run by "cronies" or "for political purposes"

-in the end Dr Bright filed a whistleblower lawsuit which result in his removal from Barda.

- Dr Rick Bright is now a Biden Transition COVID-19 Advisory Board member

-Ridgeback has licensed Molnupipiravir to Merck,but still has a substantial interest in the drug including being responsible for the Phase 1 and 2 clinical trials.

"Ridgeback will continue to fund and conduct multiple Ridgeback-sponsored Phase 1 and 2 trials and fund manufacturing campaigns for clinical supply. Going forward, the parties will collaborate on clinical development for COVID-19 and manufacturing..."

https://www.businesswire.com/news/home/20200701005928/en/Merck-and-Ridgeback-Bio-Announce-Closing-of-Collaboration-and-Licensing-Transaction

From Wikipedia

"In his complaint, Bright also noted the dangers in pursuing EIDD-2801, an oral antiviral candidate previously supported by NIAID led by Dr. Anthony Fauci and DOD...In February, 2021, Bright co-authored an opinion editorial in the Washington Post claiming "efforts to develop a therapeutics were slow and limited.]"

https://www.businesswire.com/news/home/20200701005928/en/Merck-and-Ridgeback-Bio-Announce-Closing-of-Collaboration-and-Licensing-Transaction

https://www.washingtonpost.com/business/2020/06/11/coronavirus-drug-
ridgeback-biotherapeutics/

https://pulitzercenter.org/stories/emails-offer-look-whistleblower-charges-cronyism-behind-potential-covid-19-drug

https://aac.asm.org/content/aac/early/2021/02/24/AAC.02428-20.full.pdf

https://www.clinicaltrials.gov/ct2/results?recrs=&cond=&term=Molnupiravir&cntry=&state=&city=&dist=

https://en.wikipedia.org/wiki/Rick_Bright

Glta,Farrell
© 2021 InvestorsHub.com, Inc.